Evidence map›Paper›PMID 26221075›Full record

ArticleInternational journal of biological sciences2015

The Small Molecule R-(-)-β-O-Methylsynephrine Binds to Nucleoporin 153 kDa and Inhibits Angiogenesis.

Nam Hee Kim, Ngoc Bich Pham, Ronald J Quinn, Joong Sup Shim, Hee Cho, Sung Min Cho, Sung Wook Park, Jeong Hun Kim, Seung Hyeok Seok, Jong-Won Oh and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of biological sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Nucleoporins in cardiovascular disease.Journal of molecular and cellular cardiology · 2020
    Review
  5. Review
  6. Killing cancer with platycodin D through multiple mechanisms.Journal of cellular and molecular medicine · 2016
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Nam Hee Kim1. Department of Biotechnology, Translational Research Center for Protein Function Control, College of Life Science & Biotechnology, Yonsei University, Seoul 120-749, Republic of Korea.
Ngoc Bich Pham2. Eskitis Institute, Griffith University, Brisbane QLD 4111, Australia.
Ronald J Quinn2. Eskitis Institute, Griffith University, Brisbane QLD 4111, Australia.
Joong Sup Shim3. Faculty of Health Sciences, University of Macau, Av. Universidade, Taipa, Macau SAR, China.
Hee Cho1. Department of Biotechnology, Translational Research Center for Protein Function Control, College of Life Science & Biotechnology, Yonsei University, Seoul 120-749, Republic of Korea.
Sung Min Cho1. Department of Biotechnology, Translational Research Center for Protein Function Control, College of Life Science & Biotechnology, Yonsei University, Seoul 120-749, Republic of Korea.
Sung Wook Park4. Department of Ophthalmology, Seoul National University College of Medicine, Seoul 110-799, Republic of Korea.
Jeong Hun Kim4. Department of Ophthalmology, Seoul National University College of Medicine, Seoul 110-799, Republic of Korea.
Seung Hyeok Seok5. Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul 110-799, Republic of Korea.
Jong-Won Oh1. Department of Biotechnology, Translational Research Center for Protein Function Control, College of Life Science & Biotechnology, Yonsei University, Seoul 120-749, Republic of Korea.
Ho Jeong Kwon1. Department of Biotechnology, Translational Research Center for Protein Function Control, College of Life Science & Biotechnology, Yonsei University, Seoul 120-749, Republic of Korea ; 6. Department of Internal Medicine, Yonsei University College of Medicine, Seoul 120-752, Republic of Korea.
Yonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

R-(-)-β-O-methylsynephrine (OMe-Syn) is a naturally occurring small molecule that was identified in a previous screen as an inhibitor of angiogenesis. In this study, we conducted two animal model experiments to investigate the in vivo antiangiogenic activity of OMe-Syn. OMe-Syn significantly inhibited angiogenesis in a transgenic zebrafish model as well as in a mouse retinopathy model. To elucidate the underlying mechanisms responsible for the antiangiogenic activity of OMe-Syn, we used phage display cloning to isolate potential OMe-Syn binding proteins from human cDNA libraries and identified nucleoporin 153 kDa (NUP153) as a primary binding partner of OMe-Syn. OMe-Syn competitively inhibited mRNA binding to the RNA-binding domain of NUP153. Furthermore, depletion of NUP153 in human cells or zebrafish embryos led to an inhibition of angiogenesis, in a manner similar to that seen in response to OMe-Syn treatment. These data suggest that OMe-Syn is a promising candidate for the development of a novel antiangiogenic agent and that inhibition of NUP153 is possibly responsible for the antiangiogenic activity of OMe-Syn.

Indexed as

AnimalsEphedrineMiceNeovascularization, PathologicNuclear ProteinsProtein BindingSynephrineZebrafishEphedrineNuclear ProteinsoxilofrineSynephrineAngiogenesisNatural productNUP153Small moleculeTarget identification

Identifiers

PMID26221075
PMCPMC4515819
OpenAlexW1571148603

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.